<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10952772</article-id><article-id pub-id-type="pmc">2363528</article-id><article-id pub-id-type="pii">6691341</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1341</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gridelli</surname><given-names>C</given-names></name></contrib><contrib contrib-type="author"><name><surname>Frontini</surname><given-names>L</given-names></name></contrib><contrib contrib-type="author"><name><surname>Perrone</surname><given-names>F</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gallo</surname><given-names>C</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gulisano</surname><given-names>M</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cigolari</surname><given-names>S</given-names></name></contrib><contrib contrib-type="author"><name><surname>Castiglione</surname><given-names>F</given-names></name></contrib><contrib contrib-type="author"><name><surname>Robbiati</surname><given-names>S F</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gasparini</surname><given-names>G</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ianniello</surname><given-names>G P</given-names></name></contrib><contrib contrib-type="author"><name><surname>Farris</surname><given-names>A</given-names></name></contrib><contrib contrib-type="author"><name><surname>Locatelli</surname><given-names>M C</given-names></name></contrib><contrib contrib-type="author"><name><surname>Felletti</surname><given-names>R</given-names></name></contrib><contrib contrib-type="author"><name><surname>Piazza</surname><given-names>E</given-names></name></contrib><contrib contrib-type="author"><collab>on behalf of the Gem Vin Investigators</collab></contrib><contrib contrib-type="author"><collab>See Appendix for complete list of Authors and Institutions</collab></contrib></contrib-group><pub-date pub-type="epub"><day>17</day><month>08</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>09</month><year>2000</year></pub-date><volume>83</volume><issue>6</issue><fpage>707</fpage><lpage>714</lpage><history><date date-type="received"><day>06</day><month>01</month><year>2000</year></date><date date-type="rev-recd"><day>10</day><month>05</month><year>2000</year></date><date date-type="accepted"><day>17</day><month>05</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged &#x0003c; 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-levels of Gem Vin, administered on days 1 and 8 every 3 weeks, were (mg m<sup>&#x02013;2</sup>): level I = 1000/25; level II = 1200/25; level III = 1000/30; level IV = 1200/30. A feasibility study was performed at each dose-level, followed by a single-stage phase II study. Dose-level IV was unfeasible because of grade 4 neutropenia. Overall, out of 126 patients enrolled in phase II studies, there were one complete and 32 partial responses (response rate 26&#x00025;: 95&#x00025; CI 18&#x02013;34&#x00025;). Response rates were 27.9&#x00025;, 21.4&#x00025; and 29.3&#x00025; at levels I, II and III, respectively. The treatment was well tolerated. Toxicity was less frequent and severe at level I. Overall median survival was 33 weeks (95&#x00025; CI 28&#x02013;40). Descriptive quality of life analysis showed that patients with a worse baseline global health status score tended to drop out of the study earlier than those with a better score. Gem Vin is feasible at different doses. It is sufficiently active and well tolerated. A phase III study to compare the effect on quality of life of Gem Vin (level I) vs cisplatin-based chemotherapy is ongoing. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>gemcitabine</kwd><kwd>vinorelbine</kwd><kwd>non-small cell lung cancer</kwd></kwd-group></article-meta></front></article>


